Condition: Recurrent or Metastatic Nasopharyngeal Carcinoma · Sponsor: Ming-Yuan Chen
This is a prospective, Bayesian adaptive, phase II clinical trial designed to evaluate the safety and efficacy of four treatment regimens in patients with recurrent (unamenable to local therapy) or metastatic nasopharyngeal carcinoma (NPC) who have failed after at least one prior platinum-containing standard regimen and anti-PD-1/PD-L1 therapy. The four treatment arms include: 1. Ivonescimab monotherapy, 2. Ivonescimab combined with nimotuzumab, 3. Liposomal mitoxantrone plus anti-PD-1 antibody, and 4. Liposomal irinotecan plus S-1.
This description comes directly from the study's public registry record.
Mingyuan Chen · +86 18124188280 · chmingy@mail.sysu.edu.cn
Always discuss trial participation with your own doctor first.
| Cancer Center of Guangzhou Medical University | Guangzhou, Guangdong, China | Not Yet Recruiting |
| Guangdong Provincial People's Hospital | Guangzhou, Guangdong, China | Not Yet Recruiting |
| Sun Yat-sen University Cancer Center | Guangzhou, Guangdong, China | Not Yet Recruiting |
| Zhongshan People's Hospital | Zhongshan, Guangdong, China | Not Yet Recruiting |
| The Fifth Affiliated Hospital of Sun Yat-sen University | Zhuhai, Guangdong, China | Recruiting |
| Xiangya Hospital, Central South University | Changsha, Hunan, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07070479